The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. A long-term open study

The safety and efficacy of auranofin in the long‐term treatment of children with juvenile rheumatoid arthritis was investigated in an open study of 14 patients. Twelve patients completed at least 12 months of treatment, and 7 patients completed 36 months of treatment. Classic parameters of disease activity showed improvement over baseline values after 6 months of treatment, and laboratory indices remained stable or improved throughout the study. Auranofin was well tolerated; the frequency of adverse effects was lower in these patients than has been previously reported in either adults or children whose arthritis has been treated with injectable gold. Copyright © 1988 American College of Rheumatology.